Novo Nordisk supports transparency and is committed to compliance by
disclosing our financial relationships related to our collaborations
with the medical community as required by our industry guideline,
namely the ABPI Code of Practice. We believe transparency of financial
relationships between those with whom we collaborate is very important
to maintaining trust-based relationships with our patients and the
public.
Novo Nordisk works alongside Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) to improve the development and delivery of life-enhancing and life-saving medicines for patients.
To ensure that patients have confidence in these relationships, the pharmaceutical industry, and ourselves at Novo Nordisk, are taking the lead on disclosing details of payments and other benefits in kind made to HCPs and HCOs.
In-line with current ABPI requirements, Novo Nordisk submits information regarding transfers of the value made to healthcare organisations and healthcare professionals to the ABPI central disclosure platform. For further information, please visit www.disclosureuk.org.uk.
In line with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, Novo Nordisk UK are providing details of the Patient Organisations it partners with, including the nature and financial element of each instance of support.
Patient Organisation Methodological Note
2023 Transfer of Value provided to UK Patient Organisations
2022 Transfer of
Value provided to UK Patient Organisations
2021 Transfer of Value provided to UK Patient Organisations
Collaborative Working refers to pharmaceutical companies working with other organisations to deliver initiatives which either enhance patient care or are for the benefit of patients or alternatively benefit the National Health Service (NHS) and, as a minimum, maintain patient care.
Please find below details of Novo Nordisk's Collaborative Working
Projects. For queries on any of the projects listed, please contact:
collaborativeworking@novonordisk.com.
Completed projects
-
Cities Changing Diabetes Leicester output
report
- Cities Changing Diabetes Manchester output report
-
National
Pharmacy Association (NPA) National Weight Management &
obesity campaign 2021 - 2023
- Plymouth Hypoglycaemia Assessment and Intervention for Positive Outcomes (HAIPO) Project: 2021 - 2023
- SMART MDT in T2D: 2021 - 2023
- Mid and South Essex Integrated Care System (ICS) - Integrated Weight Management Services Pathway Redesign - 2022 - 2023
- Haemophilia Outcomes Management System at the Royal Free Hospital, London: 2021 - 2023
Novo Nordisk is committed to transparency in our clinical research and continues to comply with the laws and regulations related to the registration and disclosure of Novo Nordisk sponsored clinical study information.
Summary results from completed Novo Nordisk clinical trials are available via clinicaltrials.gov and euclinicaltrials.eu.
In line with Gender Pay Gap Reporting (GPGR) regulations, all UK companies with more than 250 employees are required to publish their GPGR statistics using data as of 5th April 2022. The metrics cover the gap in pay, the gap in bonus payments, as well as the proportion of genders represented at different pay quartiles, and receiving bonus pay-outs over the previous 12 months period (6 April 2021 to 5 April 2022).
At Novo Nordisk Limited, we are committed to equality, diversity and inclusion across our workforce. We have a number of activities focused on ensuring that employees are paid equally for work of the same value irrespective of gender, and we do not tolerate discrimination on gender or any other protected grounds.
